Why protecting your child from certain preventable cancers should be a top priority
As a parent, you plan various aspects of your child's future. But it is easy to overlook a key investment during their teen years: their health. This is an important time in their life when the foundations for future well-being can be laid which can make a huge difference.
You were diligent with the childhood immunisation shots, and that protection continues. But did you know that there is prevention available including vaccination for certain types of cancers like cervical cancer, anal cancer? These are caused by HPV or the human papilloma virus – a commonly transmitted virus that often functions silently and may not show any symptoms. While most HPV infections clear on their own, but if it persists, it can lead to certain types of cancers and other complications.
Like any good investment, in health as well, acting early can yield better results. Taking preventive steps for your child during adolescence with
HPV vaccination
, between 9 and 14 years old, can yield better protection against certain HPV related cancers and diseases compared to when vaccinated later. At this age, their bodies build a more lasting immunity, providing strong protection before they are at risk of certain HPV related cancers and diseases.
And this is not just for girls. HPV poses a risk of various cancers in both men and women. Protecting both boys and girls helps reduce some of these HPV related risks.
We often see investment in health as 'optional' step because it's not an immediate risk, but a small investment today is nothing compared to the cost of a future illness. Prevention and protection are one of the important tools we have today against certain HPV related cancers.
If you have questions, you are not alone. The best first step is a simple chat with your child's paediatrician, who can answer your questions and guide you. Don't wait, the earlier this protection begins, the better it may be. It is a simple step that can help protect your child against risk of certain HPV related cancers and diseases.
Issued in public interest by MSD Pharmaceuticals for awareness purposes.
References:
1. Questions and Answers about Human Papillomavirus (HPV). WHO (regional office for Europe) 2020, accessed on 2nd July 2025
2. HPV FAQ & Questions | Help You Understand Diagnosis & Treatment. https://www.hpv.org.nz/ Accessed on 2nd July 2025
IN-GSL-01402 25-Jul 2025 24-Jul 2027
Disclaimer : The views and opinions expressed in the story are independent professional judgments of the experts, and TIL does not take any responsibility for the accuracy of their views. This article has been produced on behalf of MSD Pharmaceuticals by Times Internet's Spotlight team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
4 hours ago
- The Hindu
HPV vaccination drive held for girl students of municipal schools
Digumarti Foundation, in association with Manavseva of Boston, organised a cervical cancer prevention programme for adolescent girls from municipal schools in Akkireddypalem and Gajuwaka at KIMS ICON Hospital on Sunday. Over 200 girls received the Human Papillomavirus (HPV) vaccine, which protects against most cervical cancer cases. Mothers were also screened for cervical pre-cancer using the HPV DNA test by Dr. Leela Digumarti, enabling early detection and treatment. BJP State president P.V.N. Madhav, the chief guest, urged the public to adopt preventive measures such as natural diets and traditional practices to reduce cancer risk. Dr. Raghunath Rao, founder-director of Homi Bhabha Cancer Hospital, said children aged 9–14 will be given two doses over six months, while those aged 15–21 will receive three doses. Once imported, the HPV vaccine is now manufactured in India and has been administered to over 5,000 people. It is effective against six types of cancer.
Hindustan Times
7 hours ago
- Hindustan Times
Focus on rabies control, not stray dog population
The current debate about whether stray dogs in Delhi should have a home on the street or be rounded up into pounds has generated strong feelings on all sides. Regardless of which way a three-judge bench of the Supreme Court rules, the fundamental challenge remains curbing of rabies, the disease reported to be responsible for the death of the six-year-old which sparked this debate. Removing the roughly million stray dogs from Delhi's streets will only reduce rabies cases and deaths by less than 2% nationwide. A more productive public health approach would be to focus on rabies rather than stray dogs. India has had enormous success in infectious disease control through vaccinations, examples being smallpox, polio, maternal tetanus and most recently, Covid-19. The country can then surely make significant progress towards the World Health Organization (WHO)'s goal of zero rabies deaths by 2030 without eliminating the 60 million stray dogs in India. But we are far from that goal. India accounts for one in three rabies deaths globally and over two-thirds in Asia. According to WHO data, there are an estimated 18,000-20,000 deaths from rabies each year in India. In comparison, China, which has 40 million stray dogs, reported an average of only 433 rabies cases per year between 2015 and 2021. The number of rabies deaths has declined from 3,300 in 2007 to fewer than 300 deaths in 2020. How did China manage to control rabies without killing its stray dogs? It adopted a one-health approach to rabies control, ensuring close coordination between the human and animal health departments, widening access to post-exposure vaccines (rabies is the only infectious disease that can be addressed using a vaccine post-exposure to the virus), expanding vaccination of all stray dogs and improving surveillance of all dog bites and rabies. China administers approximately 12-15 million rabies vaccine doses every year, at a cost of about $1 billion. India's rabies control programme is poorly funded and, unlike other disease control programmes, straddles two ministries — health and animal husbandry. With poor coordination, the programme has been a failure as evidenced by the rising numbers of rabies cases. A few municipalities like Mumbai and Goa have successfully reduced rabies cases and deaths, but nationally, rabies control has been a failure. The issue pits the right of humans to live safely without getting bitten or attacked against that of most dogs who do not bite anyone. The deaths of children and the elderly due to dog attacks is painful and unacceptable. It is also unacceptable that we consign millions of dogs to a painful death in dog pounds and shelters. For many human communities, strays are part of the community without a designated pet owner. They provide security against outsiders, protection from wild animals, and are generally fed by multiple households. In many instances, most stray dogs exist because of the support of people across the country, and not just because of a small group of urban, well-heeled animal lovers. It will be impossible to get community participation to control rabies if people view the government's programme as an effort to kill their dogs. Taking this approach in a country with deeply ingrained respect for all life, we may achieve control of neither stray dog population nor of rabies. The seeds of the current situation were sown by the poorly conceived Animal Birth Control (ABC) Rules, 2001 (updated in 2023) which prevents rabid dogs from being euthanised. Rabid dogs can only be isolated until they die, often a painful death. Even dogs that bite people can be removed from an area after a lengthy investigation and bureaucratic process, which all but ensures that the dog remains in the area. These laws have likely caused an increase in bites and rabies and have diminished public support for stray dogs. In the name of love for animals, the leadership that pushed through that act without much debate has created an untenable situation that forces us to choose between human and animal life. A public health solution that puts the focus on rabies and dogs that attack humans is far more likely to succeed. In the short term, we must replace the misguided ABC rules with a more common-sense set of guidelines that allow removal of biting and rabid dogs from communities. In the longer term, India should aim to remove all dogs from streets with the aim of eliminating all rabies deaths and ensuring that both humans and dogs are protected. Ramanan Laxminarayan is president of the One Health Trust. The views expressed are personal.
The Hindu
9 hours ago
- The Hindu
Precigen shares jump after U.S. FDA approves first therapy for rare respiratory disease
Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for the condition, which typically requires frequent surgeries, sending the company's shares soaring 83% on Friday. The U.S. Food and Drug Administration has approved the therapy, Papzimeos, to treat adults with recurrent respiratory papillomatosis (RRP) — a condition that causes growth of benign tumors in the respiratory tract due to human papillomavirus (HPV) infection. A distinguishing aspect of RRP is the tendency for the tumors to return even after removing them through surgical procedures. The disease can be fatal as there is no cure. The FDA approval was based on an early-to-mid-stage study data that showed 51% of patients required no surgeries in the 12 months after the treatment. "Randomised trials are not always needed to approve medical products and this approval is proof of that philosophy," said Vinay Prasad, who recently returned to the FDA to oversee vaccine, gene therapy and blood product regulation. Papzimeos is designed to stimulate an immune response against cells infected with HPV types 6 and 11 — the strains that cause the disease. H.C. Wainwright analysts estimate peak sales of the drug to reach $1.1 billion in 2033. "We may finally be able to say no more surgery," said Kim McClellan, president of the Recurrent Respiratory Papillomatosis Foundation. McClellan herself was diagnosed with RRP at the age of five and has since then had more than 250 surgeries. Precigen estimates about 27,000 adult RRP patients in the U.S. It did not immediately respond to a Reuters request for comment on the treatment's pricing. Simon Best, associate professor of Otolaryngology at Johns Hopkins Hospital, said patients were eagerly awaiting a new treatment. "There's nothing more frustrating than doing a surgery and then having the patient come back six months later."
